ライフサイエンスコーパス: pertussis vaccine

1 id, reduced diphtheria toxoid, and acellular pertussis vaccine).

2 ndomized, double-blind trial of an acellular pertussis vaccine.

3 present since the introduction of acellular pertussis vaccine.

4 f booster doses of diphtheria-tetanus toxoid-pertussis vaccine.

5 diphtheria and tetanus toxoids and acellular pertussis vaccine.

6 ectiveness each year after the final dose of pertussis vaccine.

7 components other than those included in the pertussis vaccine.

8 nses might improve the efficacy of acellular pertussis vaccines.

9 ella pertussis might have on the efficacy of pertussis vaccines.

10 ponses, which may correlate with efficacy of pertussis vaccines.

11 s after high childhood coverage of acellular pertussis vaccines.

12 dies assessing the duration of protection of pertussis vaccines.

13 the transition from whole-cell to acellular pertussis vaccines.

14 d to the lack of cross protection induced by pertussis vaccines.

15 ly aid in the development of next-generation pertussis vaccines.

16 main in understanding the immune response to pertussis vaccines.

17 eria; and tetanus, diphtheria, and acellular pertussis vaccines.

18 tetanus and diphtheria toxoids and acellular pertussis vaccines.

19 tussis can hamper infant immune responses to pertussis vaccines.

20 ella, hepatitis B, varicella, influenza, and pertussis vaccines.

21 elopment of the next generation of acellular pertussis vaccines.

22 ified form PTd, is an important component of pertussis vaccines.

23 adult tetanus, reduced diphtheria, acellular pertussis) vaccine.

24 diphtheria and tetanus toxoids and acellular pertussis vaccine 10 years ago, during adolescence.

25 having received an age-appropriate number of pertussis vaccines (AAV) (for persons aged >/=3 months)

26 pertussis protein included in new acellular pertussis vaccines (ACPVs), a series of monoclonal antib

27 The safety and immunogenicity of 5 acellular pertussis vaccines (ACVs) were compared in a multicenter

28 erage and timing of diphtheria, tetanus, and pertussis vaccine administration and various age-restric

29 Booster doses of acellular pertussis vaccine after 7 years of age may be an effecti

30 r coexistence and the limited efficacy of B. pertussis vaccines against B. parapertussis suggest a la

31 This trial of an acellular pertussis vaccine among adolescents and adults evaluated

32 deration should be given to use of acellular pertussis vaccines among school-aged children.

33 e 2781 subjects, 1391 received the acellular pertussis vaccine and 1390 received the control vaccine.

34 mps/rubella vaccine or thimerosal-containing pertussis vaccine and autism is evident.

35 Baboons receiving acellular pertussis vaccine and infants born to mothers vaccinated

36 trations, but blunts subsequent responses to pertussis vaccine and some CRM-conjugated antigens.

37 ul for the construction of more well-defined pertussis vaccines and for the interpretation of human s

38 een linked to switch to the use of acellular pertussis vaccines and the evolution of Bordetella pertu

39 March 1996 (before introduction of acellular pertussis vaccine) and between April 1998 and March 2000

40 It is a primary component of acellular pertussis vaccines, and anti-PRN antibody titers correla

41 -cell pertussis vaccines, OPV and whole-cell pertussis vaccines, and OPV and acellular pertussis vacc

42 ertussis toxin, a critical component of many pertussis vaccines, and to examine the effects of such d

43 Concentrations of anti-pertussis vaccine antibodies were measured by standardiz

44 ation, geometric mean concentrations of anti-pertussis vaccine antibodies were significantly lower in

45 rotection contrasted with a solely acellular pertussis vaccine (aP) series.

46 Whole cell pertussis vaccines are generally highly efficacious.

47 dence that the currently available acellular pertussis vaccines are not providing optimal control of

48 Acellular pertussis (aP) and whole-cell (wP) pertussis vaccines are presumed to have similar short-te

49 ted influenza, tetanus toxoid, and acellular pertussis vaccines are recommended during pregnancy.

50 rogram in the United States, where acellular pertussis vaccines are recommended for infants.

51 tetanus and diphtheria toxoids and acellular pertussis vaccines are reviewed in this second of two ar

52 ir widespread use, increasing concerns about pertussis vaccine-associated adverse events led the deve

53 Baboons were vaccinated with acellular pertussis vaccine at 2 days of age or at 2 and 28 days o

54 nd ethically preferred until next-generation pertussis vaccines become available.

55 ve introduced adolescent and adult acellular pertussis vaccine boosters.

56 ons observed with diphtheria-tetanus toxoids-pertussis vaccine but has not eliminated the extensive s

57 s was true even prior to the introduction of pertussis vaccines but has become more pronounced since

58 netics of antibody responses to an acellular pertussis vaccine by a genome-wide association study in

59 east 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the end of 15 months of age.

60 tive potential of the novel, live attenuated pertussis vaccine candidate BPZE1.

61 Vaccination with whole-cell pertussis vaccine carries an increased risk of febrile s

62 unogenicity of 13 acellular and 2 whole cell pertussis vaccines combined with diphtheria and tetanus

63 Acellular pertussis vaccines combined with diphtheria and tetanus

64 ia-tetanus vaccine or the diphtheria-tetanus-pertussis vaccine compared with 77% and 58% usage, respe

65 erse events led the development of acellular pertussis vaccines containing 1 or more purified Bordete

66 he basis of current diphtheria, tetanus, and pertussis vaccine coverage and timing, a 90% efficacious

67 vaccination at the rate of diptheria-tetanus-pertussis vaccine coverage was projected to prevent 262,

68 ne immunization schedule: diphtheria-tetanus-pertussis vaccine dose 1 (DTP1), DTP2, DTP3, and measles

69 Case-patients having received at least 1 pertussis vaccine dose had a higher odds of having PRN(-

70 gests that the current schedule of acellular pertussis vaccine doses is insufficient to prevent outbr

71 pite high diphtheria, tetanus, and acellular pertussis vaccine (DTaP) coverage, indicating the possib

72 ffect of vaccination in the era of acellular pertussis vaccines (DTaP and Tdap), we assessed if vacci

73 eived different diphtheria-tetanus-acellular pertussis vaccines (DTaP) during childhood and should be

74 t dose of diphtheria and tetanus toxoids and pertussis vaccine (DTP 1) by 3 months of age failed to r

75 where high coverage with diphtheria-tetanus-pertussis vaccines (DTP) was maintained (Hungary, the fo

76 e of three doses of diphtheria, tetanus, and pertussis vaccine (DTP3) based on surveys using all avai

77 of GAVI on combined diphtheria, tetanus, and pertussis vaccine (DTP3) coverage.

78 ge with the third dose of diphtheria-tetanus-pertussis vaccine (DTP3) to district-reported coverage a

79 nly (three doses of diphtheria, tetanus, and pertussis vaccines [DTP3] commencing in 1985, 1995, or 2

80 it is not included in any current acellular pertussis vaccines due to protein stability issues and a

81 Children who received whole-cell pertussis vaccine during infancy or who received any per

82 analysis of published studies that evaluated pertussis vaccine efficacy or effectiveness within 3 yea

83 or more numerous booster doses of acellular pertussis vaccine either as part of routine immunization

84 ster with tetanus, diphtheria, and acellular pertussis vaccine for adolescents and adults) should be

85 er, vaccine effect varies between individual pertussis vaccine formulations, and many originally stud

86 theria toxoid, tetanus toxoid, and acellular pertussis vaccine has been associated with some suppress

87 In Denmark, acellular pertussis vaccine has been included in the combined diph

88 ame time and vaccine studies showing that B. pertussis vaccines have little effect on B. parapertussi

89 ined thiomersal (diptheria-tetanus-acellular pertussis vaccine, hepatitis B vaccine, and in some chil

90 0 cases (17%) and 39 controls (71%) received pertussis vaccine in pregnancy.

91 We calculated the effectiveness of pertussis vaccine in preventing parapertussis among Oreg

92 March 2000 (after introduction of acellular pertussis vaccine) in Ontario, Canada.

93 accumulating literature on waning acellular pertussis vaccine-induced immunity, confirming the resul

94 t whether this risk applies to the acellular pertussis vaccine is not known.

95 lysis of the short-term protective effect of pertussis vaccines limited to formulations currently on

96 ation-level safety benefits of the acellular pertussis vaccine may have been underestimated because o

97 Pertussis vaccine may induce cross-immunity.

98 Current acellular pertussis vaccines may not protect against transmission

99 Impact of pertussis vaccines on mortality is a key World Health Or

100 fely profiles of combined IPV and whole-cell pertussis vaccines, OPV and whole-cell pertussis vaccine

101 ed either a dose of a tricomponent acellular pertussis vaccine or a hepatitis A vaccine (control) and

102 have had prolonged cough, immunization with pertussis vaccine, or treatment with erythromycin.

103 safety and cost-effectiveness of whole-cell pertussis vaccines, our study shows that, far from being

104 antenatal care programs to deliver maternal pertussis vaccines, particularly with respect to infants

105 Pertussis toxoid, an acellular pertussis vaccine prepared by hydrogen peroxide treatmen

106 Blunting of the infant pertussis vaccine response was detected in group B sibli

107 scents and adults evaluated the incidence of pertussis, vaccine safety, immunogenicity, and protectiv

108 It appears that a wholly acellular pertussis vaccine series is significantly less effective

109 eks of age, before initiation of the primary pertussis vaccine series.

110 Dengue, tuberculosis, and pertussis vaccine-specific CD4(+) T cells were readily d

111 esponse and clinical protection conferred by pertussis vaccine, surveillance and a nested serosurvey

112 id, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) be administered during pregnanc

113 anus, reduced-dose diphtheria, and acellular pertussis vaccine (Tdap) could be an effective way of mi

114 iveness (VE) of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis among

115 n the safety of tetanus-diphtheria-acellular pertussis vaccine (Tdap) in persons aged >/=65 years are

116 iminated, by the presence of a sixth dose of pertussis vaccine (Tdap).

117 re personnel (HCP) vaccinated with acellular pertussis vaccine (Tdap).

118 ese adhesins are components of new acellular pertussis vaccines that have proven safe and highly effe

119 To overcome the limitations of the current pertussis vaccines, those of limited duration of action

120 nal or neonatal immunization, with acellular pertussis vaccines, to prevent life-threatening pertussi

121 children aged 7-18 months, VE for 3 doses of pertussis vaccine was 79% (95% confidence interval, 74%-

122 mmunization with a three-component acellular pertussis vaccine was characterized.

123 The acellular pertussis vaccine was protective among adolescents and a

124 ports from 1938 to 1955, when the whole-cell pertussis vaccine was rolled out, and related them to co

125 The acellular pertussis vaccine was safe and immunogenic.

126 ooster immunization of adults with acellular pertussis vaccines was not found to increase bactericida

127 id, reduced diphtheria toxoid, and acellular pertussis) vaccine was recommended for women during each

128 infants vaccinated with ACPVs or whole cell pertussis vaccine (WCPV), and sera from patients with pe

129 , adult female baboons primed with acellular pertussis vaccine were boosted in the third trimester of

130 cases of encephalopathy following whole-cell pertussis vaccine were due to severe myoclonic epilepsy

131 d the third dose of diphtheria, tetanus, and pertussis vaccine were randomly assigned to receive meas

132 Childhood acellular pertussis vaccines were licensed and implemented in the

133 Acellular B. pertussis vaccines were not efficiently protective again

134 ll pertussis vaccines, and OPV and acellular pertussis vaccines were similar.

135 es (most commonly pneumococcal and acellular pertussis vaccines), whereas standalone IPV vaccines acc

136 which combines diphtheria-tetanus-whole cell pertussis vaccines with HbOC [Hib oligosaccharide CRM197

137 ed whether prior vaccination with whole-cell pertussis vaccine (wP) at any point provided superior pr